Plasma cell (PC) neoplasms are clonal expansions of terminally differentiated B cells that typically produce monoclonal immunoglobulins (M proteins). Systemic PC neoplasms involve the bone marrow to varying degrees and include monoclonal gammopathy of undetermined significance (MGUS), smoldering plasma cell myeloma (PCM), and symptomatic PCM. 1 The International Myeloma Working Group (IMWG) uses a combination of laboratory and clinical measures to classify PC neoplasms and monitor therapeutic responses during therapy. [2] [3] [4] [5] Multiparameter flow cytometry (MFC) contributes to both primary diagnosis and therapeutic monitoring of PC neoplasms. As part of a diagnostic evaluation, MFC studies assist with classification in patients with an IgM-MGUS, 6, 7 contribute to risk assessment in patients with MGUS/ smoldering PCM, 8, 9 and confirm the lineage of neoplastic cells in suspected plasmacytomas and PCM. In patients with PCM under therapy, the distinctive phenotypic signatures of neoplastic PCs and the analytic speed of modern flow cytometers make MFC an attractive platform for minimal residual disease (MRD) detection.
MRD refers to neoplastic disease that cannot be detected with routine microscopy. In PCM, MRD detected by MFC correlates with adverse outcomes following chemotherapy and autologous stem cell transplantation. [10] [11] [12] Results such as these prompted the IMWG to incorporate MRD testing into therapeutic response evaluations along with traditional microscopic evaluations of bone marrow contents and a variety of highly sensitive immunologic assays for serum and urine M proteins. 3, 4 The deepest response levels require no detectable M protein in serum and urine, no morphologic evidence of residual disease in the bone marrow biopsy specimen, and no immunophenotypic evidence of persistent disease in the bone marrow biopsy specimen or aspirate. Both immunohistochemistry (IHC) analysis of the bone marrow biopsy specimen 3 and, more recently, MFC analysis of at least 10 6 aspirated bone marrow cells are proposed for evaluation of PCs. 4 In a small preliminary study, patients who achieved a so-called immunophenotypic complete response (negative MFC analysis for persistent disease) experienced longer progression-free survival and time to progression than those with MFC evidence of persistent disease. 10 Thus, published studies suggest that MFC analysis of bone marrow aspirates provides a sensitive measure of therapeutic response in PCM.
In the current study, the performance of a nine-color, 11-parameter MFC assay was compared with concurrent bone marrow microscopic examinations, IHC studies, and M-protein measurements for detection and monitoring of PC neoplasms. The results indicate that a two-tube assay using stain-lysefix processing of undiluted bone marrow aspirates and high collection rates achieved detection frequencies exceeding morphologic and IHC methods in bone marrows. In addition, clonal or aberrant PCs were detected in virtually all patients with M-protein levels greater than 1 g/dL and in a significant fraction of patients when one or more M-protein measures were negative. However, MFC did not detect persistent disease in bone marrow aspirate specimens in all patients with M proteins on serum or urine studies, indicating that these tests provided complementary measures of residual disease in the study.
Materials and Methods

Patients
After approval by the University of Michigan Human Research Program, we conducted a retrospective study using data from 361 consecutive patients with suspected or diagnosed PC neoplasia. Heparin-anticoagulated bone marrow aspirates were submitted to our clinical flow cytometry laboratory for immunophenotyping. MFC studies ordered for primary diagnosis and therapeutic monitoring were included in the series.
Flow Cytometry
The antibody cocktails and vendors are shown in ❚Table 1❚. The nine-color, 11-parameter assay combines surface staining for CD19, CD20, CD38, CD45, CD56, CD117, and CD138 with cytoplasmic light chain evaluation. It is performed in two tubes: one containing the analytic monoclonal antibody (Mab) cocktail and the other containing isotype controls combined with anti-CD45ECD, anti-CD38PC5.5, and anti-CD138APC.
Heparin anticoagulated bone marrow aspirates (400 mL) were washed once in standard buffer (SB; phosphate-buffered saline, 10% sodium azide, and 1% heat-inactivated fetal bovine solution) and divided between the tubes containing the analytic and control Mab cocktails for surface staining. Cells were incubated for 15 minutes (dark, room temperature) followed by RBC lysis (0.9% ammonium chloride), one wash with SB, and fixation in 1% paraformaldehyde (minimum of 15 minutes; 4°C) prior to cytoplasmic staining. The fixed cells were washed once in SB and resuspended with anti-κ and λ monoclonal antibodies (Mabs) or the isotype control cocktails in permeabilization buffer (SB + 0.006% saponin). After 30 minutes at 4°C, the cells were washed, resuspended in a minimum of 400 µL SB, and run promptly on the Gallios 10-color calibrated flow cytometer (Beckman Coulter, Miami, FL) using CXP software (Beckman Coulter). Instrument calibration was performed weekly and checked daily.
Light scatter, CD45, CD38, and CD138 signals were used for PC gating in the control sample. Two PC-"enriched" regions were defined initially based on low to intermediate side scatter and CD45 levels. The primary analysis region included CD45 negative to dim cells and generally showed the most definitive separation of the CD38+ and/or CD138+ PC "cloud," even when these markers were aberrantly reduced in intensity ❚Image 1A❚ and ❚Image 1B❚. It was used unless there were insufficient PCs for analysis or the primary and secondary regions contained PCs with distinct phenotypes. The secondary analysis region included cells with dim to moderate CD45 levels, thus incorporating some myeloid elements within the gate. The PC cloud in this region may be less distinct than in the primary region due to higher background fluorescence and CD38 expression by myeloid cells. However, PC neoplasms were often found in this region as well. This pregating step facilitated the subsequent detection of the PC cluster based on CD38 and/or CD138 expression (Images 1A and 1B). An additional gate was set on the mature lymphocyte area using the CD45 vs side-scatter histogram. The PC and lymphocyte gates were used to set fluorescence intensity thresholds for subsequent analysis of the analytic cocktail. The gate settings based on the isotype control were applied prospectively to the cells stained with the analytic cocktail so that analysis was complete shortly after cell collection ended. Cell collection with the analytic cocktail continued until 1.8 × 10 6 events were analyzed or the stained sample was consumed.
A sample was considered optimal for interpretation when more than 100 PCs were counted. The initial analysis template included histograms depicting light scatter, surface CD45, CD38, CD138, CD19, CD20, CD56, CD117, and cytoplasmic κ and λ levels in the PC and mature lymphocyte populations. Cytoplasmic κ and λ distribution was displayed for all PCs ❚Image 1C❚ and for the CD19-, CD20+, CD56+, and CD117+ PC fractions, if present, to determine whether a light chain restriction was present within these potentially aberrant fractions ❚Image 1D❚, ❚Image 1E❚, ❚Image 1F❚, and ❚Image 1G❚. In addition, trainees and attending pathologists reanalyzed list mode files to evaluate light chain distribution on atypical PC subsets as needed using combinations of the surface markers available in the file (eg, CD45, CD38, CD138, CD19, CD20, CD56, and/or CD117). As demonstrated in ❚Image 2❚ and ❚Image 3❚, comparison of light chain distributions within the total PCs and an atypical subpopulation can confirm residual disease suspected based on surface phenotype. In many instances, the aberrancies alone were sufficient to identify residual disease. However, the concurrent assessment of cytoplasmic light chains provided further corroboration of residual disease, particularly when the pretreatment phenotype of the neoplastic PC was available for comparison.
A study was "positive for clonal PCs" when (1) at least 100 PCs were analyzed and (2) a κ/λ ratio greater than 5 or less than 0.2 was found (PC gate or an aberrant PC fraction). The PC fraction within A is identified using CD38 and/or CD138 (B). Surface membrane expression of CD19, CD20, CD56, and CD117 is assessed in the PC fraction (D, E). Neoplastic PCs in this case demonstrate expression of CD20 (dim, subset), CD56 (moderate), and CD117 (dim, subset); CD19 is not detected. The cytoplasmic k and l distribution is displayed for the entire PC fraction (C), the CD20+ subset (F), and CD56+ subset (G).
A study was "suspicious for clonal PCs" when 50 to 100 PCs were analyzed and a κ/λ ratio greater than 5 or less than 0.2 was found. The study was "negative for clonal PCs" if more than 100 PCs were analyzed and the κ/λ ratio was between 0.2 and 5. A specimen was "inadequate for interpretation" when less than 50 PCs were collected or 50 to 100 PCs were collected with a κ/λ ratio between 0.2 and 5. The flow cytometry findings were made independent of concurrent morphologic and M-protein studies.
Histomorphologic and Immunohistochemical Evaluation
PC percentage was estimated using a 500-cell differential count performed on the bone marrow aspirate smear. Plasmacytosis was defined as more than 5% PCs. 3 The morphologic diagnosis of PC neoplasia was rendered based on the presence of plasmacytosis, PC atypia and, if available, clonal expression of light chain determined by IHC. The decision to perform IHC was made on a case-bycase basis by the attending hematopathologist. The 4-mm core biopsy sections were prepared according to standard laboratory protocols. IHC for CD138 (1/100 dilution; Cell Marque, Rocklin, CA) and k and l immunoglobulin light chains (1/32,000 and 1/64,000 dilutions, respectively; DAKO, Carpenteria, CA) were performed using the Ventana ultraView DAB (polymer) detection system for CD138 and the Ventana iVIEW DAB (indirect biotin streptavidin) detection system for k and l on a BenchMark ULTRA automated immunostainer (Ventana Medical Systems, Tucson, AZ).
Immunopathology Laboratory Evaluation
Serum Free Light Chains
Serum samples were assessed for free light chains (FLCs) using a BN II nephelometer (Dade Behring, Deerfield, IL).
The FLC reagent sets (FREELITE) were from The Binding Site (Birmingham, England). The assays were done using latex-enhanced immunoassays. The principle and protocol of this technique have been described by Bradwell et al. 13 The diagnostic interval for κ/λ FLC ratios used in the study was 0.26 to 1.65. The 95% reference interval was 3.3 to 19.4 mg/L for κ FLC and 5.7 to 26.3 mg/L for λ FLC. These ranges were established by Katzmann et al. 14 
Capillary Electrophoresis for Serum and Urine Protein Electrophoresis
Capillary electrophoresis (CE) was performed using the automated Sebia Capillary System (Sebia, Norcross, GA). Manufacturer guidelines were followed in performing the analysis as previously described. 15 CE interpretation was carried out in all cases by three pathologists familiar with the technique. The pathologist interpreting the CE pattern had no knowledge of the flow cytometry results or of the clinical situation of the patient.
Serum Immunofixation
Serum immunofixation (IFE) was performed on serum with the Sebia Hydragel-Hydrasys 2 IFE system (Sebia) using nine-sample agarose gels. The precipitated protein was visualized with acid violet stain, and the M protein was characterized using anti-IgG, anti-IgM, anti-IgA, anti-κ, and anti-λ (Sebia).
Urine Protein Electrophoresis and IFE
Detection of Bence-Jones proteins (BJPs) was performed using an aliquot of concentrated urine from a 24-hour urine collection as previously described. 16 For this study, the precipitated protein was visualized with acid violet stain (Sebia Hydragel-Hydrasys 2 IFE system) using anti-IgG, anti-IgM, anti-IgA, anti-κ, and anti-λ (Sebia). To be considered a BJP, the M-protein restriction needed to react with either anti-κ or anti-λ and lack reactivity with antisera to the heavy chains. 17
Results
Flow Cytometry Assay Performance and Immunophenotypic Findings
MFC was performed on 361 bone marrow aspirate specimens of patients with known or suspected PC neoplasia. Demographic information, diagnosis, and treatment status of the patients are summarized in ❚Table 2❚. Most patients (75%) had a diagnosis of PCM and were receiving chemotherapy or an autologous stem cell transplant (posttransplant specimens). In most of these patients, the phenotypic profile of the neoplastic clone was defined before treatment commenced. MFC was subsequently requested for the detection of residual disease, generally in concert with microscopic bone marrow examination and M-protein studies. The remainder of patients had MFC ordered as part of the diagnostic workup for a suspected PC neoplasm. The specimens included in this study were bone marrow aspirates. A first-pull aspirate was recommended for optimal residual disease detection. However, most specimens in the study were second pull or later since first-pull aspirates are generally used for smear preparation at the bedside. Once in the laboratory, total preparation time for the assay was approximately 90 minutes, which included approximately 30 minutes of "hands-on" time. The technologist performing the assay was able to prepare and run up to three specimens concurrently. Up to 1.8 × 10 6 total bone marrow events were analyzed in each tube containing the analytic Mab cocktail (fewer cells were analyzed from the control tube).
The percentage of cases in which less than 10 5 , 10 5 to 5 × 10 5 , 5 × 10 5 to 10 6 , and more than 10 6 events per tube were analyzed was 5%, 32%, 31%, and 32%, respectively. The mean instrument analysis time was around 6 minutes/tube with a range of 0.6 to 15 minutes. Acquisition rates varied from 81 to 16,000 events/s (average 2,700 events/s) with good maintenance of data quality at the higher rates (based on visual inspection). However, clogging in the fluidics system occurred more often with concentrated samples and high collection rates. Processing of a single 200-mL aliquot of bone marrow yielded 100 or more PCs in 78% of specimens (280 cases).
Immunophenotypic characteristics of clonal and nonclonal PCs are summarized in ❚Table 3❚. The table shows the overall percentage of samples in which at least 20% of the PC population (nonclonal or clonal) expressed the indicated marker. CD38 and CD138 expression levels varied in both clonal and nonclonal PCs. CD19 was expressed above the PC-gated isotype control on the surface of PCs in 44% of nonclonal and 9% of clonal populations. The frequency of CD19 expression by polyclonal PC in our series is lower than reported previously for nonneoplastic PCs. 18 The use of PC-gated isotype controls may be a factor since these showed higher background fluorescence than commonly used internal control populations (eg, unlysed erythroid cells or mature lymphoid cells in the analytic cocktail). Differences in the performance of the fluorochrome conjugates used or an impact of compensation settings cannot be excluded. As reported previously, 18 loss of CD19 and expression of CD56 are commonly observed in clonal PC populations; however, both features occurred in subsets of polyclonal populations as well. CD20 and CD117 were detected in 25% or less of clonal PC fractions, but these markers were rarely observed in polyclonal PCs. CD38 levels were somewhat more variable in clonal than in polyclonal populations, whereas CD138 intensities varied in both. As described in the next section, all of these surface markers were useful in revealing light chainrestricted subsets within the PC population.
Histologic Results and Comparison With Flow Cytometric Analysis
❚Table 4❚ compares the results of MFC and the bone marrow morphologic findings. The table shows the distribution of MFC results (positive or suspicious, negative, or inadequate) for each of the morphologic findings or interpretations listed across the top. Please note that both MFC "positive" and "suspicious" studies met the κ/λ criteria for the presence of a PC clone (see Flow Cytometry section in Materials and Methods). The difference is that the former had more than 100 total PCs in the analysis, whereas the latter contained 50 to 100 PCs and thus did not meet the IMWG-suggested threshold for determination of PC clonality. 3 MFC analysis detected a PC clone in most (MFC positive or suspicious, 87%) but not all (MFC negative, 8%) of the specimens with a plasmacytosis of more than 5%. MFC analysis also detected PC clones in 40% of cases without a plasmacytosis (PCs ≤5%). Most of the bone marrow biopsy specimens with clonal PCs detected by IHC were positive by MFC analysis of the aspirate as well MFI, qualitative assessment of mean fluorescence intensity for nonclonal or clonal plasma cells.
and CD117 on subsets of total PCs. Gates defined by one or more of these potential aberrancies enriched for k-restricted PCs, confirming the presence of residual disease. Please note that gates defined by multiple phenotypic features-for example, CD19-CD20+ (Image 3C,D) or CD56+CD117+ (Image 3G,H)-provided the most pronounced k enrichment in this example. This reflects the finding that CD56 expression and loss of CD19, the two most prevalent anomalies in our series of PC neoplasms, occurred in subsets of nonclonal PCs as well (see Table 3 ).
The benefits of correlated analysis are further demonstrated in ❚Table 5❚. The table contains cases in which κ/λ ratios in the total PC fraction either did not make or barely exceeded the threshold for diagnosis (ie, κ/λ ratios between 0.1 and 10). Thirty-two (18%) of 181 cases available for review met this criterion. The table shows that gating on PC fractions expressing one or more atypical features enriched for clonal populations by 10-to 100-fold. Importantly, this group contained many cases in which morphologic findings were insufficient for diagnosis (59% of the specimens in the cohort). Thus, gating on minor subsets of PCs expressing one or more atypical surface features was often required for diagnosis when a low level of residual disease was mixed with polytypic PCs.
❚Figure 1❚ compares the percentage of PCs estimated by MFC and microscopic differential counts. The percentage of nucleated cells within the "PC" gate was defined based on expression of negative to dim CD45, moderate to bright CD38, and/or CD138 (see Materials and Methods). The morphologic estimate was derived from a 500-cell microscopic differential performed by experienced hematopathologists. The axes in Figure 1 are logarithmic to accommodate the low numbers and broad distribution of PCs in the specimens. The data show that the two measures yielded widely different estimates for PC percentage. Morphologic PC counts were consistently higher than MFC estimates, with differences ranging from 1.5-to more than 100-fold, despite the use of methods thought to preserve PCs during processing, including the use of a stain-lyse-fix approach, reduced wash steps, and gentle manual resuspensions when necessary. 19 (95%). In contrast, significant percentages of the IHC-(19%) and IHC± (44%) cases had MFC studies that were positive or suspicious. Finally, virtually all cases with a morphologic diagnosis of PC neoplasm had a PC clone detected by MFC in the aspirate (96%). However, a substantial percentage of cases interpreted as negative (23%) or equivocal (31%) based on microscopic findings alone or in combination with IHC had MFC evidence of clonal PCs as well.
As noted, 19% of the IHC-and 44% of the IHC equivocal bone marrow biopsy specimens had PC clones detected by MFC in the aspirate. In many of these cases, the discordance occurred because a small, aberrant clonal population was mixed with an excess of polyclonal PCs. Images 2 and 3 show how the correlated analysis possible with the nine-color analytic cocktail enhanced detection of residual PCM when polyclonal PCs were present. In Image 2, the κ/λ ratio was unremarkable (2:1) when all PCs were included in the analysis gate. Gating on the CD56+ and/or CD117+ PCs revealed a k-restricted subset identical to the PCM in the pretreatment marrow. In Image 3, the κ/λ ratio in the PC gate was skewed (4.9:1) but below the threshold of 5:1 set for diagnosis. Atypical surface marker expression was noted for CD19, CD20, CD56, A key performance measure for a residual disease assay is the frequency of inadequate studies. We modified the arbitrary target recommended by the IMWG (analysis of at least 100 PCs) 3 and allowed a diagnosis of "suspicious" when 50 to 100 PCs were recovered and a light chain restriction and/or aberrant PCs were readily identified. However, we required a minimum analysis of 100 PCs before concluding that a study was negative (ie, polyclonal cytoplasmic PC distribution without definitive aberrancies). Using these criteria, 82% of the specimens submitted for MFC were adequate for analysis. The specimens with insufficient PCs generally had a low morphologic PC percentage, had a negative IHC study, and were interpreted as negative for a PC neoplasm (Table 4) . While many of the "inadequate" specimens were hemodilute, others were cellular and representative of bone marrow but still did not contain enough PCs for analysis. the serum FLC, SPEP/IFE, and urine tests for M proteins appeared complementary since no single approach revealed all patients with clonal paraproteins. Serum M-protein levels are one measure of tumor burden in secretory PCM. Therefore, serum samples were divided into four groups based on M-protein levels to facilitate comparison with concurrent bone marrow studies (Table 6 , bottom section). Cases with the lowest serum M-protein levels were those in which CE was negative, but close visual inspection of the IFE gel revealed an M protein (SPEP-/IFE+; 21%). Cases in the remaining three groups were positive by protein electrophoresis and IFE, and thus M-protein quantitation was possible (SPEP+): less than 0.4 g/dL (23%), 0.4 to 1 g/dL (27%), and more than 1 g/dL (28%).
Serum and Urine Immunology Results and Comparison With Flow Cytometry
BJP quantification (UPEP/BJQ) were available in 325 and 247 cases, respectively. Serum FLC assays were available in 50 cases with concurrent SPEP, IFE, UPEP, and BJQ analyses. Clonal M proteins were present in 62% of the specimens by SPEP/IFE and approximately 40% by UPEP/ BJQ. Among the 243 cases with concurrent SPEP/IFE and UPEP/BJQ analyses, either the serum or urine was positive in 67%, both the serum and the urine were positive in 32%, only the serum was positive in 28%, and only the urine was positive in 7%. The FLC ratio was abnormal in 76% of the 50 cases analyzed. The limited data available for FLC analysis in our group concur with more authoritative studies in this area, [13] [14] [15] [16] [17] suggesting that it equals or exceeds the M-protein detection frequency of SPEP/IFE alone. Overall, based on PC phenotype into criteria for a stringent complete response (sCR) and an immunophenotypic complete response (iCR). An sCR requires clonal PC analysis by either IHC or immunofluorescence methods, 3 whereas an iCR specifies clonal PC analysis by MFC using a minimum of four colors and 10 6 total bone marrow cells. 4 In the current study, MFC performed on the bone marrow aspirate detected clonal PCs in 19% of specimens interpreted as negative and 44% interpreted as equivocal for residual disease based on IHC analysis of the bone marrow core biopsy specimens (n = 83). In contrast, MFC failed to detect clonal PCs in only 1% of cases called positive by IHC (n = 69). MFC analysis also detected clonal PCs in 40% of cases with PC counts less than 5% (n = 229) and in 23% of cases in which no morphologic evidence of disease was found (n = 197). MFC analysis detected a PC clone in 87% of cases with more than 5% PCs (n = 86) and 96% of cases interpreted as positive based on the overall morphologic impression (n = 145). Thus, MFC was superior to conventional microscopic and IHC evaluations for the detection of low-level disease. The enhanced residual disease detection frequency afforded by MFC vs IHC may help explain the clinical benefit of an iCR over sCR in the study conducted by Paiva et al. 10 The analytic cocktail in this study contained Mabs targeted at three PC gating epitopes (CD38, CD45, and CD138), four potential markers of aberrancy in PC neoplasms (CD19, CD20, CD56, and CD117), and cytoplasmic light chains. It would take two to four six-color analytic tubes to replicate the performance of this single nine-color cocktail. At a minimum, the three gating epitopes would be required in each six-color tube. If one wanted to ensure that a potentially aberrant surface marker was associated with a light chain-restricted PC population, then the anti-light chain reagents would be needed as well. The nine-color cocktail eliminated the need for multiple aliquots of the PC gating and the anti-light chain reagents, thus reducing the overall cost of the test vs a fiveor six-color format. In addition, the assay used two rather than three to five aliquots of the aspirate and produced fewer stained samples for collection and analysis. An approach that conserves aspirate for possible concentration and minimizes the number of stained samples per specimen is particularly valuable for MRD testing in which analysis of large numbers of bone marrow cells is required for optimal sensitivity. Finally, as demonstrated in Images 2 and 3 and Table 5 , the nine-color cocktail facilitated light chain evaluation of minor PC fractions expressing atypical surface phenotypes. This enhanced detection of residual PCM when it was mixed with an excess of normal PCs. The concurrent biopsy specimens in these patients were often interpreted as negative based on morphologic and immunocytochemical evaluations, suggesting that an excess of polyclonal PCs can obscure small populations of residual disease in the core biopsy specimen.
❚Figure 2❚ compares the results of M-protein studies (serum and urine) and MFC analysis of bone marrow specimens performed no more than 1 week apart. Most of these patients were under treatment for PCM, and testing was ordered to monitor therapy. Figure 2A shows the results of MFC studies in bone marrow aspirates when one or more M-protein measurements were negative. MFC detected clonal PCs in 23 (20%) cases with negative SPEP/IFE, 53 (38%) cases with negative UPEP/BJQ, and 10 (11%) cases with both negative SPEP/IFE and negative UPEP/BJQ. As noted previously, FLC results were available in a limited number of patients. MFC detected PC clones in the bone marrows of five (42%) of 12 patients with negative FLC studies alone and one (20%) of five patients negative by all M-protein detection methods (SPEP, IFE, UPEP, BJQ, and FLC). Thus, MFC analysis of bone marrow specimens may find evidence of persistent PCM in the absence of detectable M protein, particularly if only serum or urine measurements are performed. Figure 2B shows the results of MFC studies on the bone marrow in patients with positive M-protein studies. The first two bars show that approximately 60% of the patients with the lowest M-protein levels had monoclonal PCs detected by MFC in the bone marrow (MFC+). The remainder of patients had either no detectable clonal PCs (MFC-, 25%-30%) or inadequate PCs for analysis (11%). In contrast, 80% to 90% of patients in the two groups with the highest serum M-protein levels had monoclonal PCs in the bone marrow and relatively few negative or inadequate studies. The last two bars in Figure  2B show that, overall, 73% to 80% of patients with M protein in the urine or serum had clonal PCs in the bone marrow. An additional 5% to 10% had no detectable clonal PCs in the bone marrow, and the remaining cases had inadequate PCs for MFC analysis. Thus, MFC analysis of bone marrow in patients with PCM with more than 1 g/dL of serum M protein appears unnecessary unless the phenotypic signature of the neoplastic population has not been defined.
Discussion
This study describes a two-tube, nine-color MFC assay suitable for primary diagnosis and residual disease detection of PC neoplasms in bone marrow aspirates. The assay correlates CD19, CD20, CD38, CD45, CD56, CD117, CD138, and (cytoplasmic) immunoglobulin light chain expression on up to 1.8 × 10 6 total bone marrow cells. Use of undiluted bone marrow aspirates, stain-lyse-fix processing, minimal wash steps, and high collection rates created a streamlined workflow and permitted time-efficient acquisition of the large number of cellular events needed for diagnosis.
As part of their effort to improve monitoring of therapeutic trials, the IMWG incorporated MRD testing rates above 10,000 events/s and collection of 1.8 × 10 6 events in less than 5 minutes. Insistence on first-pull aspirates or, as suggested above, insertion of a concentration step prior to staining might further decrease collection times, albeit at the expense of additional upfront processing time unless an automated total bone marrow cell count is feasible. 23 We included light chain analysis to expand the utility of the assay for primary diagnosis and complement surface marker evaluation for the detection of residual disease given the reported stability of light chain restriction as a marker in serial studies of patients with PCM. 24, 25 In addition, an isotype control gated on PCs was used because PCs showed higher backgrounds than unlysed erythroid cells or lymphocytes and lower backgrounds than myeloid cells or monocytes, potential "internal" controls available in all specimens. However, many experienced laboratories use primarily surface marker analysis (Mabs in study cocktail plus CD27, CD81 at a minimum) and internal negative controls for residual disease detection. 18, 19, 21, 22, 26 A direct comparison of the assay described herein with these approaches is beyond the scope of this report. A workshop is currently under way that will compare current practices and publish recommended standards for MRD testing in PC myeloma (Maryalice StetlerStevenson, MD, PhD, and Paul K. Wallace, PhD, personal communication, January 2, 2014). We are participants and fully endorse the project.
PC percentage estimates by MFC were 1.5-to 100-fold lower than concurrent 500-cell differential counts despite the use of staining and processing practices outlined by the European Myeloma Network. 19 Other laboratories report similar experiences. 18, 27 Hemodilution was a factor in our series since first-pull aspirates were used for smear preparation. In addition, the denominator for the PC percentage calculation was the event number in a "total-cell" gate based on light scatter. This approach was readily incorporated into workflow but most likely overestimated cell numbers since unlysed RBCs, apoptotic cells, platelet clumps, and debris may be present. Despite these shortcomings, MFC estimates of PC percentage may provide useful prognostic information. 28 A novel approach using "bone marrow precursors" to normalize PC counts may help compensate for artifacts arising from the gating approach used in our study. 29 Nonetheless, until collection and analysis parameters are standardized, we conclude that MFC can detect residual disease in bone marrow aspirates without morphologically detectable PCs, but that PC percentage estimates may not be accurate.
Our study did not evaluate clinical outcomes, but published reports indicate that MRD status is predictive of overall outcome in clinical trials. 10, 11, 21 In one study, the predictive value for remission-free survival appeared superior to M-protein levels, 10 possibly due to the slow clearance of M proteins from the circulation. 11 However, in a study Approximately 18% of the cases in our series had such mixtures, suggesting that regeneration of nonneoplastic PCs or a lenalidomide-induced plasmacytosis 20 can occur in the presence of residual disease. We conclude that a nine-color analytic cocktail can reduce the cost and increase the analytic power of PC evaluation by flow cytometry.
Our experience generally supports the last published IMWG recommendations for MFC studies, 4 although we favor specifying both a minimum number of PCs and a maximum number of total bone marrow cells for an adequate study. The minimum PC collection targets used in this study, 100 total PCs or 50 PCs if a clone was readily identified, were achieved in 82% of cases often after collections of fewer than the 10 6 total bone marrow cells currently recommended by the IMWG. In other cases, collection of more than 10 6 total bone marrow cells was needed to ensure sufficient PCs for phenotypic evaluation. Adding a target based on a minimum number of PCs shortens collection times in cases with ample PCs and focuses effort on cases where PCs are present in low levels.
The assay used fixed 200-mL aliquots of undiluted bone marrow aspirate, without further adjustment, for both the control and analytic tubes. Cell recoveries determined maximum cell counts, which varied from 1 × 10 5 to a maximum of 1.8 × 10 6 (collection limited by software). Formal calculation of sensitivity is beyond the scope of this study; however, based on a 100-PC minimum for the detection or exclusion of residual disease, the estimated limit of detection for PC neoplasms with aberrancies detected by the analytic cocktail varied from approximately 100/1 × 10 5 to 100/1.8 × 10 6 (0.1% to 0.006% of the processed specimen). Uniform and, if necessary, higher levels of sensitivity could be achieved by setting a minimum target for total bone marrow cell analysis as reported by others. 18, 19, 21, 22 Instrument acquisition rates in our series varied over a broad range due to bone marrow cellularity and hemodilution in the specimens submitted. Specimens with low acquisition rates had the lowest total cell counts, lowest sensitivities, and the highest frequency of "inadequate" specimens. Concentration of washed and lysed specimens prior to staining has been used by other groups to compensate for hemodilution, increase PC recovery, and maximize sensitivity (Maryalice StetlerStevenson, MD, PhD, personal communication, January 2, 2014). Our findings suggest that inclusion of such a step would be beneficial.
Consolidating the full panel into a single cocktail eliminated duplication of PC gating antibodies and reduced the total number of tubes per case by 50% over our previous five-color method. Stain-lyse-fix processing of the bone marrow aspirate without a cell count or adjustment for concentration shortened processing time but resulted in highly variable acquisition rates. Nonetheless, processing of high-quality, concentrated aspirates resulted in acquisition of patients receiving autologous stem cell transplants, the absence of both M proteins and MRD was required for the most favorable outcomes. 21 In our series, approximately 60% of bone marrow aspirates showed MFC evidence of persistent disease when M-protein measurements were below 0.4 g/ dL or detected by IFE only (ie, visible but insufficient for quantitation). In addition, residual disease was detected by MFC in a substantial percentage of patients in whom either the serum or urine studies were negative for M proteins (Figure 2 and Results). Combining the results of several distinct serum and urine M-protein tests reduced but did not eliminate the possibility that MFC analysis would detect residual disease. We conclude that MFC analysis of a bone marrow aspirate complements immunologic monitoring of M proteins in serum and urine when the latter are present at low levels or absent.
In summary, MFC performed on bone marrow aspirates improved the overall detection frequency of PC dyscrasia/ neoplasms. It was superior to standard morphologic and IHC evaluations of the bone marrow aspirate/biopsy specimen. Furthermore, MFC complemented M-protein analysis for the detection of persistent disease at low levels.
